Amarin Corp. and Kowa Pharmaceuticals to Begin Joint Vascepa Promotion in May


Follow this company

Companies Mentioned

NASDAQ:AMRN / NASDAQ:NVAX / NASDAQ:BLDP
04/11/2014 [ACCESSWIRE]

Amarin Corp. PLC (NASDAQ:AMRN) stock volume was tepid Apr. 10, with just 1,595,690 shares, a third of its three-month average volume of 4,405,235 shares.

The UK-based biopharmaceutical is a company with expertise in lipid science that is focused on commercialization and development of therapeutics to improve cardiovascular health.

Amarin recently made an agreement with Kowa Pharmaceuticals America Inc., to co-promote Amarin's flagship product, Vascepa capsules in the United States.

Join Vascepa Promotion

Vascepa is approved for use in the United States as an adjunct to diet to reduce triglyceride levels in adult patients with hypertriglyceridemia. In bringing together two companies focused on the primary care and cardiovascular health communities, the agreement is designed to benefit a greater number of patients.

The agreement provides for the near-term expansion of Vascepa promotional efforts through use of Kowa Pharmaceuticals America's sales force to substantially increase both the number of sales targets reached and the frequency of sales calls on existing sales targets.

Under the agreement, Kowa Pharmaceuticals America will employ its sales force of approximately 250 sales representatives to co-promote Vascepa in the United States augmenting Amarin's approximately 130 sales representatives and more than doubling Amarin's current sales detail frequency through primary and secondary details.

Kowa Pharmaceuticals America's sales force is expected to begin its Vascepa promotional efforts in May 2014 to its existing target audience of primary care physicians and cardiologists.

Analysts' Consensus

Of the 9 analysts that cover AMRN, 2 recommend a "strong buy," while 7 recommend a "hold".

On Apr.10, AMRN's share price closed at $1.75, down 1 cent from the share price of $1.76 the previous day.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:
http://www.pennypickalerts.com

Novavax Inc. Outlines Its Recent Achievements and Anticipated Events

In the biopharma sector, Novavax Inc. (NASDAQ:NVAX) stock volume was robust Apr. 10, with 4,139,026 shares changing hands.

The recent uptick in stock volume comes on the heels of the Malvern Penn.-based firm is a clinical-stage biopharmaceutical company engaged in creating differentiated, value-upon current preventive options for various infectious diseases.

Novavax recently initiated a Phase 1/2 clinical trial of its H7N9 avian influenza VLP vaccine candidate with its proprietary Matrix-M adjuvant.

The trial is enrolling 610 healthy subjects to evaluate the safety and immunogenicity of this vaccine and adjuvant.

Novavax released the following summary of its recent achievements and anticipated events:

2014 Recent Events:

-- Extended the contract for Advanced Development of Recombinant Influenza Products and Pandemic Preparedness with HHS BARDA; and

2014 Anticipated Events:

-- Release of top-line data from the ongoing Phase 2 clinical trial of the RSV F protein nanoparticle vaccine candidate in women of childbearing age in the second quarter of 2014;

-- Release of top-line data from the recently initiated Phase 1/2 clinical trial of the H7N9 avian influenza VLP vaccine candidate with Matrix-M in the second half of 2014;

-- Initiate a Phase 2 clinical trial of our RSV F protein nanoparticle vaccine in pregnant women in the fourth quarter of 2014; and

-- Initiate a Phase 2 clinical trial of our quadrivalent VLP seasonal influenza vaccine in the fourth quarter of 2014.

On Apr.10, NVAX's share price closed at $4.04, down 32 cents from the share price of $4.36 the previous day.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

Ballard Power Systems' Fuel Cells Power Buses for Aberdeen Hydrogen

In the alternative energy sector, Ballard Power Systems Inc. (NASDAQ: BLDP) announced that Van Hool NV, the fourth-largest bus manufacturer in Europe, delivered the first four buses powered by Ballard's 150-kilowatt FCvelocity-HD6 fuel cell module.

Van Hool will deliver the other six buses in the fleet of ten known as the "Aberdeen Hydrogen Bus Project" to transit agencies in Aberdeen, Scotland in the next few weeks.

The Canadian-based fuel-cell company is engaged in the design, development, manufacture, sale and service of fuel cell products for a variety of applications, focusing on motive power and stationary power.

Analysts' Consensus

The two analysts that cover BLDP both recommend a "hold".

On Apr. 10, BLDP's share price closed at $4.14, down 6 cents from its previous day's share price of $4.20, on volume of 4,438,409 shares.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

 

ABOUT US:

Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.

Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.pennypickalerts.com

Disclosure

Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.

COMMENTS

Leave a comment...
 * 

Your Name
 *